Pomegranate (Punica granatum L.) has been valued for centuries in traditional medicine, with different parts of the fruit used to address a variety of ailments. In recent years, modern scientific research has focused on its potential role in cancer prevention and treatment. Laboratory and animal studies suggest that pomegranate juice and its extracts may inhibit processes involved in lung cancer development and progression. However, these findings remain preliminary, and robust clinical evidence demonstrating that pomegranate prevents or treats lung cancer in humans is still limited.
Pomegranate is particularly rich in biologically active compounds, including anthocyanins, ellagitannins, hydrolysable tannins, and other polyphenols. These substances contribute to the fruit's strong antioxidant and anti-inflammatory properties. Oxidative stress and chronic inflammation can contribute to DNA damage and abnormal cell growth, processes that are important in cancer development. By reducing oxidative stress and inflammation, pomegranate compounds may help create an environment less favorable to tumor formation.
One notable area of research involves the effect of pomegranate extracts on lung tumors. In landmark preclinical research from the University of Wisconsin–Madison, oral administration of pomegranate extract substantially reduced lung tumor growth in mice. Tumor growth was reduced by approximately 53.9% after 84 days and by as much as 61.6% after 140 days. Although impressive, these results occurred in an animal model and cannot be assumed to produce the same effect in people.
Other animal studies have examined the damaging effects of cigarette smoke on the lungs. Chronic exposure to tobacco smoke can cause oxidative stress, inflammation, abnormal cell proliferation, and changes that promote cancer development. Pomegranate juice supplementation in experimental models was associated with fewer lung nodules, reduced cellular division, and suppression of hypoxia-inducible factor-1 alpha (HIF-1α), a protein that can help tumors adapt to oxygen-poor environments.
Researchers have also identified several molecular pathways that may explain these effects. Pomegranate-derived compounds appear to influence signaling systems such as NF-κB, MAPK, and PI3K/Akt/mTOR, which regulate inflammation, cell survival, proliferation, and metabolism. Altering these pathways may encourage apoptosis, or programmed death of abnormal cells, while limiting uncontrolled cancer-cell growth.
Another potential mechanism is anti-angiogenesis. Growing tumors need new blood vessels to obtain oxygen and nutrients and to facilitate their spread. Experimental evidence indicates that pomegranate compounds may interfere with the formation of these blood vessels, potentially restricting tumor development.
Despite these encouraging findings, pomegranate juice should not be considered a proven lung-cancer treatment. Human studies remain insufficient to establish effective doses, long-term benefits, or safety alongside cancer therapies. People with lung cancer should therefore discuss supplements or concentrated extracts with their healthcare team rather than replacing established treatments. Pomegranate remains a promising subject for cancer research, but further well-designed clinical trials are needed to determine whether its laboratory benefits translate into meaningful protection or treatment effects in humans.Pomegranate Juice and Lung Cancer: Promising Preclinical Evidence
